- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Interleukin 2, Proleukin
Synonyms :
aldesleukin
Class :
Biological Response Modifiers
Dosage Forms & Strengths
Powder for injection
22 million International Units/vial
Indicated for Metastatic Renal Cell Carcinoma
6 lakh international units/Kg of body weight (0.037 mg/Kg) three times a day intravenously infused over 15 min for highest of 14 doses, after that 9 days rest period; after that highest of 14 extra doses
Retreatment: Assess after four weeks, preferable only if the tumor shrinkage occurs
Metastatic Melanoma
6 lakh international units/Kg of body weight (0.037 mg/Kg) three times a day intravenously infused over 15 min for highest of 14 doses, after that 9 days rest period; after that highest of 14 extra doses
Retreatment: Assess after four weeks, preferable only if the tumor shrinkage occurs
It is also indicated for Non-Hodgkin Lymphoma as an orphan and also for primary immunodeficiency as an orphan
Safety and efficacy not established
Refer to adult dosing
it may increase the adverse effect when combined with aldesleukin
it may increase the adverse effect when combined with aldesleukin
it may increase the adverse effect when combined with aldesleukin
may decrease the anti-neoplastic effect of corticosteroids
may decrease the anti-neoplastic effect of corticosteroids
sipuleucel-T: they may decrease the therapeutic effect of immunostimulants
leflunomide: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
corticosteroids may diminish the antineoplastic effect of Aldesleukin
corticosteroids may diminish the antineoplastic effect of Aldesleukin
corticosteroids may diminish the antineoplastic effect of Aldesleukin
corticosteroids may diminish the antineoplastic effect of Aldesleukin
corticosteroids may diminish the antineoplastic effect of Aldesleukin
may diminish the anti-neoplastic activity
may diminish the anti-neoplastic activity
may diminish the anti-neoplastic activity
may diminish the anti-neoplastic activity
may diminish the anti-neoplastic activity
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
may decrease the antineoplastic effect when combined with aldesleukin
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
It may decrease the antineoplastic effect when combined with Corticosteroids
may decrease the anti-neoplastic effect of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
pramoxine /hydrocortisone topical
may decrease the anti-neoplastic effect
bacitracin, neomycin, polymyxin B, and hydrocortisone topical
may decrease the antineoplastic effect of corticosteroids
may decrease the antineoplastic effect of corticosteroids
may decrease the antineoplastic effect of corticosteroids
may decrease the antineoplastic effect of corticosteroids
may decrease the antineoplastic effect of corticosteroids
fusidic acid and betamethasone
may decrease the antineoplastic effect of corticosteroids
cladribine: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
immunostimulants: they may increase the toxic effect of nadofaragene firadenovec
natalizumab: they may increase the immunosuppressive effect of immunostimulants
pimecrolimus: they may increase the immunosuppressive effect of immunostimulants
ruxolitinib: they may increase the immunosuppressive effect of immunostimulants
talimogene laherparepvec: they may increase the toxic effect of immunostimulants
tofacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
antithymocyte globulin: they may increase the toxic effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
yellow fever vaccine: they may increase the toxic effect of immunostimulants
May have an increased hypersensitivity or allergic reactions when combined with Iodinated Agents
May have an increased hypersensitivity or allergic reactions when combined with Iodinated Agents
May have an increased hypersensitivity or allergic reactions when combined with Iodinated Agents
May have an increased hypersensitivity or allergic reactions when combined with Iodinated Agents
meticrane has the potential to enhance the rate of excretion of aldesleukin; this can potentially lead to decreased levels of serum, possibly diminishing its effectiveness
It may enhance the risk of bleeding when combined with nimesulide
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
May enhances the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the risk or severity of toxic effects when combined
brincidofovir: they may decrease the therapeutic effect of immunostimulants
inebilizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
It may diminish the metabolism when combined with nilvadipine
It may enhance the risk of adverse reactions when combined with sodium
It may enhance the risk of adverse reactions when combined with sodium
Actions and Spectrum:
aldesleukin, also known as interleukin-2 (IL-2), is a cytokine that regulates the immune response. It is primarily used as a medication for certain types of cancer, such as metastatic renal cell carcinoma and metastatic melanoma. Here’s some information on the action and spectrum of aldesleukin:
Action:
Spectrum:
aldesleukin has a broad spectrum of activity, mainly related to its immune-stimulating effects. It has been primarily used in treating metastatic renal cell carcinoma and metastatic melanoma (skin cancer). However, its use is generally limited to patients with good performance status and specific clinical criteria, as it can cause significant side effects.
Frequency defined
>10%
Stomatitis (22%)
Nausea (35%)
Dyspnea (43%)
Hypotension (71%)
Vomiting (50%)
Rash (42%)
Weight gain (16%)
Increased hepatic enzymes (10-23%)
Tachycardia (23%)
Malaise (27%)
Asthenia (23%)
Diarrhea (67%)
Hypocalcemia (11%)
Abdominal pain (11%)
Leukopenia (16%)
Increased creatinine (33%)
Chills (52%)
Acidosis (12%)
Edema (15%)
Anorexia (20%)
Somnolence (22%)
Oliguria (63%)
Anxiety (12%)
Respiratory/lung disorders (11-24%)
Supraventricular tachycardia (12%)
Fever (29%)
Confusion (34%)
Thrombocytopenia (37%)
Pain (12%)
Pruritus (24%)
Bilirubinemia (40%)
Nausea and vomiting (19%)
Dizziness (11%)
Infection (13%)
Exfoliative dermatitis (18%)
1-10%
Rhinitis (10%)
Arrhythmia (10%)
Black Box Warning:
aldesleukin (IL-2) does have a black box warning related to a severe adverse reaction called Capillary Leak Syndrome (CLS). The black box warning highlights the risk of CLS, which can be potentially life-threatening.
Capillary Leak Syndrome is characterized by increased capillary permeability, resulting in the leakage of fluid and proteins from the blood vessels into surrounding tissues. This can lead to fluid accumulation, low blood pressure, organ dysfunction, and potentially severe complications.
CLS can occur during or after treatment with aldesleukin and may manifest as symptoms such as edema (swelling), hypotension (low blood pressure), tachycardia (rapid heart rate), dyspnea (difficulty breathing), and organ dysfunction. CLS can lead to respiratory distress, multiple organ failure, and death if left untreated.
Due to the seriousness of this adverse reaction, aldesleukin is typically administered under close medical supervision in specialized healthcare settings, such as intensive care units or oncology units, where appropriate monitoring and management of potential complications can be provided.
Contraindication/Caution:
Contraindication
aldesleukin (IL-2) has several contraindications, which are specific situations or conditions where medication use is not recommended due to potential risks or lack of efficacy. The contraindications associated with aldesleukin include:
Caution
Specific cautions associated with aldesleukin include:
Pregnancy consideration:
US FDA pregnancy category: Not assigned.
Lactation:
Excreted into human milk is Not known.
Pregnancy category:
